A carregar...
Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
This Practice Point commentary discusses the findings of the first phase I trial to evaluate abiraterone acetate (an inhibitor of the androgen-regulating enzyme CYP17) in the treatment of castration-resistant prostate cancer. This open-label, dose-escalation study by Attard et al. showed that abirat...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4014058/ https://ncbi.nlm.nih.gov/pubmed/18957947 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncponc1262 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|